Sites of disease as predictors of outcome in metastatic renal cell carcinoma patients treated with first-line sunitinib or sorafenib

Conclusions:
mRCC patients with liver metastases treated with first-line SO showed a better outcome compared with SU, while mRCC patients without liver metastases treated with first-line SU showed a better outcome compared with SO.

Source: Therapeutic Advances in Urology - March 24, 2015 Category: Urology & Nephrology Authors: Grassi, P., Verzoni, E., Porcu, L., Iacovelli, R., de Braud, F., Procopio, G. Tags: Original Research Source Type: research